When Scrip Gets Diluted: The Hidden Risk in Stock-for-Stock Takeover Deals

A takeover offer in Australia has been extended so many times that shareholders who already said yes are now being told they can take their yes back.

Forrestania Resources, a Western Australian miner backed by the Stokes family, is trying to buy fellow explorer Zenith Minerals in an all-stock deal. But the thing you're supposed to find odd about this isn't that the deal is dragging. It's the machinery at the center of the delay: a shareholder complaint that forced the Australian Takeovers Panel to freeze the process, which forced an extension, which forced Forrestania to grant withdrawal rights — and that withdrawal right is the only useful piece of protection the shareholders have.

Here's why.

When Forrestania announced the bid on June 9, it offered one new Forrestania share for every 4.3 Zenith shares. At the time, Forrestania traded around A$0.40 per share, which implied roughly A$0.13 per Zenith share — a 47% premium to where Zenith had been trading. Zenith's board unanimously recommended the deal.

Then, about three weeks after the bid was announced, Forrestania disclosed that it was acquiring the Edna May gold hub from Ramelius Resources for A$300 million. To pay for it, Forrestania announced a capital raise of A$310 million, issuing shares at A$0.40 each. The placement was enormous: roughly 1 billion new shares, increasing Forrestania's share count by about 77%.

Now, if you hold Forrestania shares, massive dilution means your existing shares are worth a smaller slice of a bigger pie. If you're a Zenith shareholder who accepted the scrip offer, you bought a promise: you'd receive Forrestania shares at a fixed ratio. But those Forrestania shares — the currency of the deal — had just been diluted by nearly three-quarters, and the market hadn't been told about it when the bid documents went out.

The ratio hasn't changed. The quality of the currency has.

This is where a Zenith shareholder named Harvest Lane Asset Management went to the Takeovers Panel, the independent body that oversees fairness in Australian takeover bids. Harvest Lane's complaint, which ran through late July and early August, hit several points, but the structural one was the dilution. Forrestania issued bid documents on June 9. On June 29, it announced the capital raise. The raise added so many new Forrestania shares that the implied value of the Zenith offer was cut substantially — yet the offer continued, the documents weren't updated, and shareholders kept accepting based on the old implied value.

Harvest Lane also raised questions about whether Forrestania had breached standstill obligations when building a pre-bid stake of about 9.7% in Zenith, and whether Zenith's directors accepted the offer too quickly, before a reasonable window had passed for a competing bid. A second shareholder, Ida Metal Investments — which held 11.1% of Zenith — joined the fight, asking the Panel to unwind ("vest") shares Forrestania had acquired in the months leading up to the bid.

The Panel agreed something was worth investigating. In early August, it imposed interim orders that basically hit pause on the deal: Forrestania was barred from processing any new acceptances and from declaring the offer unconditional. These orders force an extension. And under Australian takeover rules, when an offer is extended, shareholders who already accepted have to be given the right to withdraw.

So here's the plumbing:

• Takeovers complaint → Panel interim orders → forced extension → mandatory withdrawal rights.

The withdrawal right exists to protect shareholders from being locked into an offer whose terms have changed. Normally it's a procedural formality — the offer hasn't materially changed, so nobody exercises it. In this case, it's potentially the most important right in the deal, because the "terms" — or at least the value of the scrip being offered — may have changed materially between the announcement and now.

The offer has been extended to August 31. (That's the fourth extension.) Forrestania says it has already secured acceptances representing 56.3% of Zenith's voting power — enough for majority control even if no more shareholders come on board. The minimum acceptance condition of 50.1% has been met, and both parties can waive it. So the deal could close even if the remaining shareholders walk away.

But the offer isn't unconditional. The Panel's interim orders are still in place, blocking Forrestania from declaring the bid free of conditions. The Panel has to be satisfied that whatever happened with the dilution and the pre-bid stake acquisition has been addressed — or at least that it won't cause unfairness if the deal proceeds.

Here's the incentive problem, which is the part most useful to sit with. Forrestania wants the deal to close. It's building a gold development platform in Western Australia, and Zenith's Consolidated Dulcie project slots neatly next to Forrestania's own assets. The Edna May processing plant, which Forrestania is simultaneously acquiring from Ramelius, would theoretically give the combined entity a way to crush and process ore without building new infrastructure. The strategic logic is clean.

The problem is on the capital side. Forrestania has been executing on an aggressive, capital-intensive expansion — A$300 million for Edna May, now all of Zenith on top of that, plus a prior acquisition of Kula Gold that closed in January. The company raised A$310 million in June to fund Edna May, but that raise also diluted the scrip it was using to pay for Zenith. The more Forrestania spends, the more it dilutes. The more it dilutes, the less its scrip is worth as currency. It's a mechanical tension, not a strategic one: every deal partially undermines the next deal's payment method.

What about the Zenith shareholders who accepted? If they exercise withdrawal rights, they're back to holding Zenith shares and hoping for a better offer — but Ida Metal, the holdout shareholder that drove much of the Panel challenge, isn't offering an alternative. It just doesn't want to sell at the current price. If nobody else steps in, the walk-away value for Zenith shareholders is whatever Zenith trades at as a standalone explorer with a single development asset and no processing infrastructure. Forrestania argues that value would be below where the stock was before the bid was announced. The Zenith board continues to recommend the offer, even after all this.

For a U.S. investor watching this, the useful takeaway isn't really about whether to buy Zenith. It's about the mechanics of scrip offers and how dilution works as an ex-post term change.

In a scrip deal, you're not getting cash. You're getting the bidder's stock at a fixed ratio. The ratio is fixed. The value of that stock is not. If the bidder issues a massive amount of new shares between the announcement and the close — for whatever reason, whether it's another acquisition or general capital needs — the consideration you accepted is worth less than what the documents implied. Australian takeover law addresses this through Panel complaints, interim orders, and withdrawal rights. It's not a perfect fix, but it's the closest thing to a recall button on a deal whose payment method has been degraded.

The deal closes August 31 if the Panel's orders don't stand in the way. Forrestania already controls more than half of Zenith on paper. The Panel has to decide whether the process was fair enough to let it stand. And somewhere in the middle, shareholders who said yes are being told they can say no — not because the offer got worse, technically, but because the currency they were paid in lost a significant portion of its value.

That's the kind of thing that makes you read the fine print of a scrip offer the next time you see one.